Patient-centered cervical cancer screening and treatment linkage program in Nairobi
Official title: Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya
Run by Kenyatta National Hospital · NCT07050745 · Data updated 2026-11-12
This project will try a multi-part care approach (DADA LINK) using care coordinators and an mHealth app to help women ages 25–49 in Nairobi get screened for cervical cancer and linked to treatment when needed.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 49 Years |
| Sex | Women only |
| Enrollment | 1980 (estimated) |
| Sponsor | Kenyatta National Hospital Government |
| Locations | 1 site (Nairobi) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT07050745 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 25–49 years receiving care at participating Nairobi clinics who are not pregnant, not within six weeks postpartum, and not already confirmed to have cervical cancer.
✕Probably not a fit
Pregnant women, women ≤6 weeks postpartum, people already confirmed to have cervical cancer, and individuals outside the 25–49 age range are not eligible and would not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Clinics in Nairobi are randomized to implement a multi-component care package (DADA LINK) that uses clinic-based care coordinators and the WEMA mHealth platform to improve HPV self-sampling uptake, screening follow-up, and linkage to treatment for precancerous cervical lesions. Trained study staff will abstract routine clinic records to monitor screening, triage, and treatment rates over a 12-month intervention period with an additional 6-month follow-up to measure costs and maintenance. Care coordinators will support clinic staff to follow cervical cancer care guidelines and will collect patient exit surveys to track intervention fidelity and uptake. The intervention was selected after formative qualitative work and clinic mapping to address barriers at the patient, provider, and facility levels in Nairobi.
Why it matters
Potential benefit: If successful, the program could increase early detection and timely treatment of precancerous cervical lesions, reducing future cervical cancer cases and deaths.
How similar studies have gone: Previous work in low- and middle-income settings has shown promise for HPV self-sampling and mHealth-supported linkage to care, but multi-component, clinic-level coordination packages like DADA LINK are less widely tested in Kenyan primary care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Women ages 25-49 years Exclusion Criteria: * Pregnant women * Women ≤6 weeks postpartum * Women already confirmed to have cervical cancer
Where it's running
-
Kenyatta National Hospital
Nairobi, Kenya Recruiting
Study contacts
- Principal investigator: Rose J Kosgei, MBChB,MMed,MSc,Fell.GynOnc,PhD — University of Nairobi
- Study coordinator: Agnes K Karume, MBChB, MBA, MPH
- Email: karumeagnes@gmail.com
- Phone: +254715181283
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Q-Pad menstrual-pad test to detect high-risk HPV and cervical precancer
This study tests whether a home menstrual-pad kit (Q-Pad) can detect high-risk HPV and cervical precancer in people referred for colposcopy after an abnormal Pap or HPV result.
-
HPV self-sampling to improve cervical screening for women in Zaporizhzhia during the war
This project will test whether giving women aged 30–60 in Zaporizhzhia HPV self-sampling kits can keep cervical screening going when clinic access is disrupted by the war.
-
AI chatbot plus home HPV self-sampling to boost cervical screening participation
This project will try to see if sending HPV self-sampling kits to women aged 30–65 in low-income areas together with a multi-language AI chatbot decision aid increases screening uptake among women who did not respond to an initial invitation.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.